• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.一种具有新型Tat诱导表达系统及对靶细胞特异性嗜性的慢病毒载体对HIV-1的抑制作用
Hum Gene Ther. 2015 Oct;26(10):680-7. doi: 10.1089/hum.2015.031. Epub 2015 Aug 6.
2
[Inhibition of HIV-1 in vitro by combination of vpr and tat specific short hairpin RNA via lentiviral vectors].通过慢病毒载体组合vpr和tat特异性短发夹RNA在体外抑制HIV-1
Bing Du Xue Bao. 2013 Mar;29(2):126-31.
3
Semen Exosomes Promote Transcriptional Silencing of HIV-1 by Disrupting NF-κB/Sp1/Tat Circuitry.精浆外泌体通过破坏 NF-κB/Sp1/Tat 通路促进 HIV-1 的转录沉默。
J Virol. 2018 Oct 12;92(21). doi: 10.1128/JVI.00731-18. Print 2018 Nov 1.
4
Tat-regulated expression of RNA interference: triggers for the treatment of HIV infection.Tat调控的RNA干扰表达:治疗HIV感染的触发因素。
Curr HIV/AIDS Rep. 2008 Feb;5(1):40-3. doi: 10.1007/s11904-008-0007-3.
5
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA.通过TAT诱导的小干扰RNA表达对HIV-1进行负反馈抑制
Nat Biotechnol. 2004 Dec;22(12):1573-8. doi: 10.1038/nbt1040. Epub 2004 Nov 28.
6
Activity of TAR in inducible inhibition of HIV replication by foamy virus vector expressing siRNAs under the control of HIV LTR.在HIV长末端重复序列(LTR)控制下,表达小干扰RNA(siRNA)的泡沫病毒载体诱导抑制HIV复制过程中TAR的活性。
Virus Res. 2009 Mar;140(1-2):112-20. doi: 10.1016/j.virusres.2008.11.016. Epub 2009 Jan 9.
7
Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.携带抗HIV短发夹RNA的慢病毒载体:问题与解决方案
J Gene Med. 2007 Sep;9(9):743-50. doi: 10.1002/jgm.1078.
8
A new-generation stable inducible packaging cell line for lentiviral vectors.一种用于慢病毒载体的新一代稳定诱导包装细胞系。
Hum Gene Ther. 2001 May 20;12(8):981-97. doi: 10.1089/104303401750195935.
9
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition.用于多种短发夹RNA表达及持久抑制HIV-1的慢病毒载体设计
Mol Ther. 2008 Mar;16(3):557-64. doi: 10.1038/sj.mt.6300382. Epub 2008 Jan 15.
10
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.根据CD4计数和病毒载量分组的不同HIV感染患者的CD4淋巴细胞中,高效慢病毒载体介导的HIV-1复制控制。
Mol Ther. 2004 Jun;9(6):902-13. doi: 10.1016/j.ymthe.2004.03.005.

引用本文的文献

1
Optimization of a lentivirus-mediated gene therapy targeting HIV-1 RNA to eliminate HIV-1-infected cells.一种靶向HIV-1 RNA以消除HIV-1感染细胞的慢病毒介导基因疗法的优化。
Mol Ther Nucleic Acids. 2024 Sep 16;35(4):102341. doi: 10.1016/j.omtn.2024.102341. eCollection 2024 Dec 10.
2
Tat-dependent conditionally replicating adenoviruses expressing diphtheria toxin A for specifically killing HIV-1-infected cells.依赖 Tat 的条件复制型腺病毒表达白喉毒素 A 特异性杀伤 HIV-1 感染细胞。
Mol Ther. 2024 Jul 3;32(7):2316-2327. doi: 10.1016/j.ymthe.2024.05.015. Epub 2024 May 11.
3
A recombinant adenoviral vector with a specific tropism to CD4-positive cells: a new tool for HIV-1 inhibition.一种具有特异性嗜 CD4 阳性细胞的重组腺病毒载体:HIV-1 抑制的新工具。
Drug Deliv Transl Res. 2022 Oct;12(10):2561-2568. doi: 10.1007/s13346-021-01109-y. Epub 2022 Jan 31.
4
A novel screening system based on gene targeting to enrich the modified mammalian cells: without leaving selection marker and additional sequence.一种基于基因靶向的新型筛选系统,用于富集修饰的哺乳动物细胞:无需留下选择标记和额外序列。
3 Biotech. 2019 Oct;9(10):357. doi: 10.1007/s13205-019-1884-4. Epub 2019 Sep 5.
5
Investigating Effect of Rapamycin and Metformin on Angiogenesis in Hepatocellular Carcinoma Cell Line.雷帕霉素和二甲双胍对肝癌细胞系血管生成的影响研究
Adv Pharm Bull. 2018 Mar;8(1):63-68. doi: 10.15171/apb.2018.008. Epub 2018 Feb 18.

本文引用的文献

1
Use of integrase-minus lentiviral vector for transient expression.利用整合酶缺失慢病毒载体进行瞬时表达。
Cell J. 2012 Summer;14(2):76-81. Epub 2012 Aug 31.
2
Expression of interfering RNAs from an HIV-1 Tat-inducible chimeric promoter.表达来自 HIV-1 Tat 诱导的嵌合启动子的干扰 RNA。
Virus Res. 2011 Jan;155(1):106-11. doi: 10.1016/j.virusres.2010.09.006. Epub 2010 Sep 22.
3
A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle.双重功能 TAR 诱饵可作为抗 HIV siRNA 递药载体。
Virol J. 2010 Feb 10;7:33. doi: 10.1186/1743-422X-7-33.
4
A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs.一种通过RNA干扰抑制HIV-1的新方法:用第二代小干扰RNA对抗病毒逃逸
J RNAi Gene Silencing. 2005 Oct 14;1(2):56-65.
5
Activity of TAR in inducible inhibition of HIV replication by foamy virus vector expressing siRNAs under the control of HIV LTR.在HIV长末端重复序列(LTR)控制下,表达小干扰RNA(siRNA)的泡沫病毒载体诱导抑制HIV复制过程中TAR的活性。
Virus Res. 2009 Mar;140(1-2):112-20. doi: 10.1016/j.virusres.2008.11.016. Epub 2009 Jan 9.
6
Nucleic acids-based therapeutics in the battle against pathogenic viruses.基于核酸的疗法在对抗致病性病毒中的应用
Handb Exp Pharmacol. 2009;189(189):243-63. doi: 10.1007/978-3-540-79086-0_9.
7
Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts.用于肝脏特异性表达靶向乙型肝炎病毒转录本的多种干扰RNA的载体设计。
Antiviral Res. 2008 Oct;80(1):36-44. doi: 10.1016/j.antiviral.2008.04.001. Epub 2008 May 6.
8
Calcium phosphate transfection.磷酸钙转染
Curr Protoc Mol Biol. 2003 Aug;Chapter 9:Unit 9.1. doi: 10.1002/0471142727.mb0901s63.
9
Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses.寡核苷酸抗病毒疗法:针对高致病性RNA病毒的反义疗法和RNA干扰
Antiviral Res. 2008 Apr;78(1):26-36. doi: 10.1016/j.antiviral.2007.12.008. Epub 2008 Jan 14.
10
Genetic therapies against HIV.针对艾滋病病毒的基因疗法。
Nat Biotechnol. 2007 Dec;25(12):1444-54. doi: 10.1038/nbt1367.

一种具有新型Tat诱导表达系统及对靶细胞特异性嗜性的慢病毒载体对HIV-1的抑制作用

Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.

作者信息

Farazmandfar Touraj, Haghshenas Mohammad Reza, Shahbazi Majid

机构信息

1 Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran.

2 Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

出版信息

Hum Gene Ther. 2015 Oct;26(10):680-7. doi: 10.1089/hum.2015.031. Epub 2015 Aug 6.

DOI:10.1089/hum.2015.031
PMID:26077977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4630793/
Abstract

Today, lentiviral vectors are favorable vectors for RNA interference delivery in anti-HIV therapeutic approaches. Nevertheless, problems such as the specific recognition of target cells and uncontrolled expression of the transgene can restrict their use in vivo. Herein we present a new HIV-inducible promoter to express anti-HIV short hairpin RNA (shRNA) by RNA Pol II in mammalian cells. We likewise showed a novel third-generation lentiviral vector system with more safety and a specific tropism to the target cells. The new promoter, CkRhsp, was constructed from the chicken β-actin core promoter with the R region of HIV-1 long terminal repeat fused upstream of minimal hsp70 promoter. This system was induced by HIV-1 Tat, and activates transcription of two shRNAs against two conserved regions of HIV-1 transcripts produced in two steps of the virus life cycle. We also mimicked HIV-1 cell tropism by using the HIV-1 envelope in structure of third-generation lentiviral vector. The new fusion promoter efficiently expressed shRNA in a Tat-inducible manner. HIV-1 replication was inhibited in transient transfection and stable transduction assays. The new viral vector infected only CD4+cells. CkRhsp promoter may be safer than other inducible promoters for shRNA-mediated gene therapies against HIV. The use of the wild envelope in the vector packaging system may provide the specific targeting T lymphocytes and hematopoietic stem cells for anti-HIV-1 therapeutic approaches in vivo.

摘要

如今,慢病毒载体是抗HIV治疗方法中用于RNA干扰传递的理想载体。然而,诸如靶细胞的特异性识别和转基因的失控表达等问题可能会限制其在体内的应用。在此,我们提出一种新的HIV诱导型启动子,用于在哺乳动物细胞中通过RNA聚合酶II表达抗HIV短发夹RNA(shRNA)。我们同样展示了一种新型的第三代慢病毒载体系统,其具有更高的安全性和对靶细胞的特异性嗜性。新的启动子CkRhsp由鸡β-肌动蛋白核心启动子构建而成,HIV-1长末端重复序列的R区域融合在最小hsp70启动子的上游。该系统由HIV-1 Tat诱导,并激活针对在病毒生命周期两个步骤中产生的HIV-1转录本两个保守区域的两个shRNA的转录。我们还通过在第三代慢病毒载体结构中使用HIV-1包膜来模拟HIV-1细胞嗜性。新的融合启动子以Tat诱导的方式有效表达shRNA。在瞬时转染和稳定转导试验中,HIV-1复制受到抑制。新的病毒载体仅感染CD4+细胞。对于针对HIV的shRNA介导的基因治疗,CkRhsp启动子可能比其他诱导型启动子更安全。在载体包装系统中使用野生型包膜可为体内抗HIV-1治疗方法提供特异性靶向T淋巴细胞和造血干细胞。